Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

1.

The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.

Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H.

Jpn J Clin Oncol. 2012 Jun;42(6):477-84. doi: 10.1093/jjco/hys035. Epub 2012 Mar 28.

PMID:
22457321
[PubMed - indexed for MEDLINE]
Free Article
2.

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.

BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.

PMID:
19035858
[PubMed - indexed for MEDLINE]
3.

A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.

Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group.

J Urol. 2008 Nov;180(5):1986-92. doi: 10.1016/j.juro.2008.07.033. Epub 2008 Sep 17.

PMID:
18801505
[PubMed - indexed for MEDLINE]
4.

Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.

Steinberg M.

Clin Ther. 2009;31 Pt 2:2312-31. doi: 10.1016/j.clinthera.2009.11.009. Review.

PMID:
20110043
[PubMed - indexed for MEDLINE]
5.

Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.

Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T.

Eur Urol. 2008 Oct;54(4):805-13. doi: 10.1016/j.eururo.2008.04.065. Epub 2008 May 8.

PMID:
18538469
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.

de la Rosette J, Davis R 3rd, Frankel D, Kold Olesen T.

Int J Clin Pract. 2011 May;65(5):559-66. doi: 10.1111/j.1742-1241.2011.02637.x. Epub 2011 Feb 22.

PMID:
21342376
[PubMed - indexed for MEDLINE]
7.

Degarelix: a new approach for the treatment of prostate cancer.

Persson BE, Kold Olesen T, Jensen JK.

Neuroendocrinology. 2009;90(3):235-44. doi: 10.1159/000228832. Epub 2009 Jul 14.

PMID:
19602868
[PubMed - indexed for MEDLINE]
8.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.

J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23.

PMID:
21788033
[PubMed - indexed for MEDLINE]
9.

A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.

Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC.

Clin Ther. 2002 Nov;24(11):1902-14.

PMID:
12501882
[PubMed - indexed for MEDLINE]
10.

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.

Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, van der Meulen E, Persson BE.

Urology. 2012 Jul;80(1):174-80. doi: 10.1016/j.urology.2012.01.092.

PMID:
22748873
[PubMed - indexed for MEDLINE]
11.

Degarelix and its therapeutic potential in the treatment of prostate cancer.

Doehn C, Sommerauer M, Jocham D.

Clin Interv Aging. 2009;4:215-23. Epub 2009 May 14. Review.

PMID:
19503784
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.

Raddin RS, Walko CM, Whang YE.

Anticancer Drugs. 2011 Mar;22(3):299-302.

PMID:
21360851
[PubMed - indexed for MEDLINE]
13.

The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.

Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB.

J Urol. 2001 May;165(5):1585-9.

PMID:
11342922
[PubMed - indexed for MEDLINE]
14.

A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.

Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC.

J Urol. 2002 Sep;168(3):1199-203.

PMID:
12187267
[PubMed - indexed for MEDLINE]
15.

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Schröder FH, Tombal B, Miller K, Boccon-Gibod L, Shore ND, Crawford ED, Moul J, Olesen TK, Persson BE.

BJU Int. 2010 Jul;106(2):182-7. doi: 10.1111/j.1464-410X.2009.08981.x. Epub 2009 Nov 13.

PMID:
19912212
[PubMed - indexed for MEDLINE]
16.

New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.

Garnick MB, Mottet N.

BJU Int. 2012 Aug;110(4):499-504. doi: 10.1111/j.1464-410X.2011.10708.x. Epub 2011 Nov 16.

PMID:
22093775
[PubMed - indexed for MEDLINE]
17.

Degarelix.

Frampton JE, Lyseng-Williamson KA.

Drugs. 2009 Oct 1;69(14):1967-76. doi: 10.2165/10484080-000000000-00000.

PMID:
19747011
[PubMed - indexed for MEDLINE]
18.

Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Pathak AS, Pacificar JS, Shapiro CE, Williams SG.

J Urol. 2007 Jun;177(6):2132-5; discussion 2135.

PMID:
17509298
[PubMed - indexed for MEDLINE]
19.

Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.

Zuckerman JM, Eure G, Malcolm J, Currie L, Given R.

Urology. 2014 Mar;83(3):670-4. doi: 10.1016/j.urology.2013.10.036. Epub 2013 Dec 19.

PMID:
24360065
[PubMed - indexed for MEDLINE]
20.

An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.

Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB; Abarelix Study Group.

Urology. 2003 Nov;62(5):877-82.

PMID:
14624912
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk